EP08.02-102 Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer

Abstract

EGFR mutations (EGFRm) represent ≈10% of advanced non-small cell lung cancer (aNSCLC) in European patients (pts). Tissue molecular profiling is the gold-standard, but liquid biopsy (ctDNA) offers a non-invasive alternative for molecular profiling. Crystal Digital PCR™ (cdPCR) is a highly-sensitive technique to detect specific molecular alterations. Here, we aimed to illustrate cdPCR clinical utility for EGFRm detection in aNSCLC.